BioMarin Pharma (BMRN) Tops Q3 EPS by 5c
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $65.51 +1.71%
EPS Growth %: +1,016.7%
Financial Fact:
Intangible asset amortization and contingent consideration: 9.65M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +1,016.7%
Financial Fact:
Intangible asset amortization and contingent consideration: 9.65M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q3 GAAP EPS of ($0.07), $0.05 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $334.1 million versus the consensus estimate of $349.59 million.
GUIDANCE:
BioMarin Pharma sees FY2017 revenue of $1.29-1.32 billion, versus the consensus of $1.31 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
- Cooper Cos. (COO) Tops Q3 EPS by 3c, Offers Guidance
- Adobe Systems (ADBE) Tops Q3 EPS by 6c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
